Image for representational purpose only (Pic: Reuters) 
News

Serum Institute seeks DCGI nod to examine and manufacture Sputnik V in India

The SII has already told the government that it will be able to manufacture and supply 10 crore Covishield doses in June

EdexLive Desk

The Serum Institute of India (SII) has applied to the Drug Controller General of India (DCGI) seeking permission for a test license to manufacture COVID-19 vaccine Sputnik V in the country, sources said on Thursday. The Pune-based firm has also sought a test license for analysis and examination. Russia's Sputnik V vaccine is currently being manufactured in India by Dr Reddy's Laboratories.

"The Serum Institute of India (SII) put up an application to the Drugs Controller General of India (DCGI) on Wednesday seeking permission for a test license to manufacture the COVID-19 vaccine, Sputnik V, in India," a source said.

The SII has already told the government that it will be able to manufacture and supply 10 crore Covishield doses in June, while it is also manufacturing the Novavax vaccine, the regulatory clearance for which is awaited from the United States. The vaccine was given emergency use authorisation (EUA) by the DCGI in April. A consignment of 30 lakh doses of Sputnik V landed in Hyderabad on Tuesday.

Why is Newcastle University facing backlash over its ‘Professor of Practice in Sustainability’ appointment? | Explained

CA January 2027 Exams: ICAI announces Foundation and Intermediate exam dates

AP OAMDC Phase 2 Seat Allotment Result 2026 Today: Check reporting dates, key instructions

TNPSC Group 1 Prelims Answer Key 2026: How soon can it come after the exam? Check 5-Year Trend

MHT CET BPharmacy CAP Round 1 Result 2026 to be released Today: Check seat acceptance, freeze and not Freeze rules